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OBJECTIVE: To perform an economical evaluation of
darunavir + low-dose ritonavir (DR) vs other protease inhibitors
(PIs) in treatment-experienced HIV-1-infected patients in the
Russian health care system. METHODS: The modeled study was
performed. A proportion of patients receiving alternative PIs,
dosing regimen, and efﬁcacy of drugs were extracted from mul-
ticenter randomized studies POWER 1 and 2 (Lancet 2007;
369:1169–78). The effect was measured in proportion of
patients with viral load reduction of 1 log 10 copies/ml or greater
from baseline and with viral load less than 50 copies/ml. Other
PIs in POWER studies were lopinavir + ritonavir, saquinavir,
amprenavir, atazanavir, indinavir, nelﬁnavir; all patients in both
groups received optimized background regimen. Cost of treat-
ment with PIs for 48 weeks and cost-effectiveness ratio (CER)
were calculated from the Russian reimbursement system point of
view. RESULTS: According to POWER studies, DR was much
more effective than other PIs (61 vs 15% of patients had viral
load reduction 1 log 10 copies/ml and 45 vs 10% achieved
viral load <50 copies/ml), while cost of treatment was a little
more for DR than other PIs (370,786.08 vs. 330,747.59 rubles or
15,105.64 vs USD 13,474.47). Incremental CER was 87,000
rubles (USD 3544.34) for one patient with viral load reduction
1 log 10 copies/ml and 114,400 rubles (USD 4660.60) for one
patient with viral load <50 copies/ml that seems reasonable for
expensive antiHIV treatment. CONCLUSION: According to the
model, DR seems to be much more effective than other PIs with
affordable CER incremental ratio. Evaluation of DR treatment
effectiveness and safety in common practice is needed.
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OBJECTIVE: Globally, an estimated 170 million persons are
chronically infected with hepatitis C virus (HNV) and 350
million—with hepatitis B (HBV). New HCV and HBV medicines
are 100%–400% more costly and have a negative impact on the
budget. The aim of this study was to calculate, in the health care
payer perspective, the cost effectiveness (CE) of new medicines
for HCV and HBV treatment in comparison with the previous
generation ones. METHODS: This analysis compares the CE of
entecavir, adefovir dipivoxil versus lamivudinum in previous
therapy refractory HBV patients and the CE of peginterferonum
alfa with interferonum alfa in chronic HCV patients. Data of
clinical effectiveness have been extracted from clinical studies
published in electronic databases (PubMed, Embase com,
Medscape, Cochrane Library) from 1990 to 2007 December.
Only direct medical costs (medicines) have been estimated. Costs
were based upon average wholesale price and State Reimburse-
ment list prices. A decision analytic model, made by TreeAge
DATA Professional program, has been used. RESULTS: The use
of new generation medicines, such as adefovir dipivoxil and
entecavir, is not cost effective for chronic HBV therapy in patients
with unsuccessful previous therapy due to high prices; however
the difference of effectiveness reaches 80%. Peginterferonum alfa
for chronic HCV compared with nonpegilated interferonum is
cost effective if the difference of effectiveness reaches 40% or the
shorter (12 week) course of pegilated interferon is needed. CON-
CLUSION: Despite the high medicines clinical effectiveness, the
new medicines are not cost effective compared with previous
generation for the chronic HCB and HBV treatment due to high
prices. Wherewith, the generic (cheaper?) medicines income to
the market is inescapable. Prospective studies including indirect
costs are necessary.
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OBJECTIVE: Candidemia is a nosocomial bloodstream infection
associated with considerable mortality and is costly to treat. A
new echinocandin, anidulafungin, has been shown to be effective
in treating candidemia and other forms of invasive candidiasis
(henceforth, candidemia). The objective of this study was to
compare cost and outcomes of anidulafungin with current
standard of care in Canada, and ﬂuconazole, for the treatment of
candidemia in non-neutropenic adult patients. METHODS: A
decision tree was constructed to examine the cost-effectiveness of
anidulafungin compared with ﬂuconazole, in the treatment of
candidemia. Data on treatment success, renal toxicity, duration
of intravenous and oral antifungal treatment, and patient sur-
vival were obtained from a published, randomized, double-blind
trial comparing anidulafungin with ﬂuconazole. Separate analy-
ses of the clinical trial data were performed to obtain length of
stay in the intensive care unit and general ward for each arm of
the trial. Therapy switching and additional resource use were
obtained from surveys of Canadian clinicians. Medical and drug
costs were taken from standard Canadian costing sources and
the published literature. The incremental cost per successfully
treated patient was calculated. Sensitivity analyses were per-
formed. RESULTS: The percentage of successfully treated
patients is higher for patients treated with anidulafungin than
with ﬂuconazole (74.02% vs. 56.78%). Treating with anidu-
lafungin results in higher antifungal drug costs $4792 vs. $2651;
however, overall costs are lower for treatment with anidulafun-
gin than for treatment with ﬂuconazole ($62,949 vs. $65,954,
respectively) due to an offset in other medical costs, mainly in
ICU where anidulafungin is associated with savings of $6707.
Thus, treating with anidulafungin is cost-savings (less costly and
more efﬁcacious) when compared to treating with ﬂuconazole.
CONCLUSION: Anidulafungin has demonstrated improved
clinical efﬁcacy versus standard of care in treating candidemia.
Despite an increase in drug costs, treating candidemia with
anidulafungin is a cost-saving strategy.
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PHARMACOECONOMIC ANALYSIS BASED ON GUIDELINES
FORTREATING MILD DIABETIC FOOT INFECTIONS:
A DECISIONTREE MODEL FOR CANADA
Chow I, Lemos EV, Marr P, Machado M, Einarson TR
University of Toronto,Toronto, ON, Canada
OBJECTIVE: Limited information exists to guide clinicians in
selecting antibiotics for diabetic foot infections. Because this
serious complication causes substantial morbidity, mortality, and
incurs major health care costs, we developed a decision tree
model to determine, from the Ministry of Health’s perspective,
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